Biotech Investment News: Amgen’s Key Deals from 2015 to 2025

Strategic Review: From Biologics to Rare Diseases, Oncology, and RNA Innovation

Over the past decade, Amgen has expanded beyond its legacy focus on bone and inflammatory diseases to invest heavily in oncology, RNA therapies, and rare diseases. With major acquisitions like Horizon Therapeutics and cutting-edge collaborations, Amgen is redefining its next growth era.

Major Acquisitions and Partnerships (2015–2025)

• 2015: deCODE Genetics (genomics platform)
• 2019: Otezla acquisition (psoriasis, divestment from BMS-Celgene merger) – $13.4B
• 2020: BeiGene partnership (Asia expansion)
• 2021: Five Prime Therapeutics (FGFR2b antibody for gastric cancer) – $1.9B
• 2021: Teneobio (multispecific antibody platform) – $2.7B
• 2022: ChemoCentryx (Oralavik for vasculitis and inflammatory disease) – $3.9B
• 2022: Generate Biomedicines AI-based protein design collaboration
• 2023: Horizon Therapeutics acquisition (rare diseases: Tepezza, etc.) – $27.8B

Strategic Significance

Amgen’s deals align with a triad strategy: rare diseases, inflammation/immunology, and oncology. Its investments in ADC, RNA, and AI-driven drug design position it well for the next decade of biotech innovation.

My Insight

Amgen’s approach to acquisitions reflects long-term vision, focusing not only on new products but also on technological platforms and global market access. The Horizon acquisition epitomizes its ambition to lead in next-gen therapeutics.

References

• Horizon Therapeutics Acquisition (2023)
• ChemoCentryx Acquisition (2022)
• Five Prime Acquisition (2021)